Health Care·Pharmaceuticals·$6.1B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.44 | N/A | +13.21% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.44 | N/A | +13.21% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about the competitive landscape and its impact on performance. They reiterated their commitment to navigating these challenges.
Management acknowledged ongoing challenges in the market.
They emphasized a focus on long-term strategies despite current setbacks.
The earnings report indicates that Terns Pharmaceutical is still facing challenges, as reflected in the EPS miss. The stock dropped 8.1% following the announcement, likely due to investor concerns over the lack of revenue data and guidance. The defensive tone from management suggests they are cautious about the near-term outlook.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
TAKE-TWO INTERACTIVE
Nov 7, 2022